Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00169026 · ClinicalTrials.gov registry record · Phase 4
Alcoholism and Schizophrenia: Effects of Clozapine
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT00169026 is a Phase 4 study that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 64 participants.
The verdict
NCT00169026, a Phase 4 study, was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the short - term effects of clozapine on alcohol use in persons with schizophrenia and an alcohol use disorder. The hypothesis is that clozapine will have greater efficacy in reducing alcohol use than other antipsychotic medications.
Interventions
- DRUG Clozapine versus typical (conventional) and atypical antipsychotic medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 1999-05 |
| Est. Completion | 2004-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00169026
The ClinicalTrials.gov registry entry for NCT00169026 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clozapine versus typical (conventional) and atypical antipsychotic medications is the first listed.
NCT00169026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00169026 about?
NCT00169026 is a clinical study titled "Alcoholism and Schizophrenia: Effects of Clozapine". The purpose of this study is to examine the short - term effects of clozapine on alcohol use in persons with schizophrenia and an alcohol use disorder. The hypothesis is that clozapine will have greater efficacy in reducing alcohol use than other antipsychotic medications.
What is the current status of trial NCT00169026?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 1999-05. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00169026?
The interventions under investigation include: Clozapine versus typical (conventional) and atypical antipsychotic medications (DRUG).
Who is sponsoring clinical trial NCT00169026?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.